Ariceum Therapeutics GmbH’s radiopharmaceutical 225Ac-SSO110 ([225Ac]satoreotide tetraxetran) has been awarded orphan drug designation by the FDA for the treatment of small-cell lung cancer (SCLC). [225Ac]Satoreotide is a first-in-class Actinium-labeled somatostatin SST2 receptor antagonist.
SSO-110, also known as DOTA-JR11 or satoreotide tetraxetran, is a somatostatin SST2 receptor (SSTR2) antagonist that targets a higher number of binding sites and stays longer in SSTR2-positive tumors compared to SST2 receptor agonists. It is currently in clinical development as [177Lu]Lu-SSO-110 for small-cell lung cancer (SCLC). Ariceum Therapeutics GmbH has revealed preclinical data on [177Lu]Lu-SSO-110 as well as another SSO-110-based radiopharmaceutical, [225Ac]Ac-SSO-110, which yielded better results than DOTA-TATE-conjugated isotopes.
Ariceum Therapeutics GmbH has received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a phase I trial (CITADEL-123) of 123I-ATT-001, its iodine-123 labeled PARP inhibitor, in patients with recurrent glioblastoma. The study is expected to begin in the U.K. in June of 2024.
Ariceum Therapeutics GmbH has submitted an application with the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a phase I trial of [123I]-ATT-001, its iodine-123-labeled PARP inhibitor in patients with recurrent glioblastoma.
Ariceum Therapeutics GmbH is picking up where Ipsen SA left off and taking forward the targeted radiopharmaceutical drug satoreotide, developed by the French pharma to phase II but subsequently divested when it ditched its radiation therapy portfolio.
